NCT00511446 - Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

January 31, 2013

Conditions

Stomach Neoplasms

Interventions

DRUG

docetaxel, oxaliplatin, capecitabine

"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."

Trial Locations (10)

13353

Charite - Universitatsmedizin Berlin, Berlin

36043

MVZ Osthessen, Fulda

44892

Medizinische Universitätsklinik - Knappschaftskrankenhaus, Bochum

55101

Universitätsklinikum Mainz, Mainz

68167

Universitätsklinikum Mannheim, Mannheim

73730

Städtische Kliniken Esslingen, Esslingen am Neckar

79539

OSP Lörrach-Rheinfelden, Loerrach

89081

Universitätsklinik Ulm, Ulm

06120

Martin-Luther-University Halle-Wittenberg, Halle

04129

Städt. Klinikum St. Georg, Leipzig

All Listed Sponsors

lead

Martin-Luther-Universität Halle-Wittenberg

OTHER